Vladimir K Bakalov1, Thomas Shawker, Irene Ceniceros, Carolyn A Bondy. 1. Developmental Endocrinology Branch, National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland 20892-1103, USA. bakalov@mail.nih.gov
Abstract
OBJECTIVE: To evaluate uterine development of women with Turner syndrome (TS) receiving conventional medical care. STUDY DESIGN: In a cross-sectional study we used ultrasonography for uterine evaluation in 86 women with TS 18 to 45 years of age participating in an intramural NIH study, and who had abnormal karyotypes in >70% of white blood cells. Outcomes were uterine dimensions and shape. Information on hormone treatment was obtained by personal interview. RESULTS: Twenty-five percent had a mature in size and shape uterus, and 31% had an immature uterus, with the remainder in a transitional category. Twenty percent of all participants were not taking hormone replacement therapy (HRT) in the preceding year. The majority on treatment were taking conjugated estrogens (CE) or oral contraceptives (OC). Factors associated with uterine maturity were history of spontaneous puberty and duration and type of HRT, with estradiol-based treatment being the most effective. The age at starting HRT was not a critical factor. CONCLUSIONS: Women with TS may develop a normal uterus even at a late start of HRT given adequate duration of treatment and regardless of karyotype.
OBJECTIVE: To evaluate uterine development of women with Turner syndrome (TS) receiving conventional medical care. STUDY DESIGN: In a cross-sectional study we used ultrasonography for uterine evaluation in 86 women with TS 18 to 45 years of age participating in an intramural NIH study, and who had abnormal karyotypes in >70% of white blood cells. Outcomes were uterine dimensions and shape. Information on hormone treatment was obtained by personal interview. RESULTS: Twenty-five percent had a mature in size and shape uterus, and 31% had an immature uterus, with the remainder in a transitional category. Twenty percent of all participants were not taking hormone replacement therapy (HRT) in the preceding year. The majority on treatment were taking conjugated estrogens (CE) or oral contraceptives (OC). Factors associated with uterine maturity were history of spontaneous puberty and duration and type of HRT, with estradiol-based treatment being the most effective. The age at starting HRT was not a critical factor. CONCLUSIONS:Women with TS may develop a normal uterus even at a late start of HRT given adequate duration of treatment and regardless of karyotype.
Authors: P Saenger; K A Wikland; G S Conway; M Davenport; C H Gravholt; R Hintz; O Hovatta; M Hultcrantz; K Landin-Wilhelmsen; A Lin; B Lippe; A M Pasquino; M B Ranke; R Rosenfeld; M Silberbach Journal: J Clin Endocrinol Metab Date: 2001-07 Impact factor: 5.958
Authors: E Porcu; S Venturoli; R Fabbri; L F Orsini; E Sganga; L Brondelli; R Paradisi; C Flamigni Journal: Am J Obstet Gynecol Date: 1989-07 Impact factor: 8.661
Authors: W Kiess; G Conway; M Ritzen; R Rosenfield; S Bernasconi; A Juul; Y van Pareren; S M P F de Muinck Keizer-Schrama; J-P Bourguignon Journal: Horm Res Date: 2002
Authors: Christian Trolle; Britta Hjerrild; Line Cleemann; Kristian H Mortensen; Claus H Gravholt Journal: Endocrine Date: 2011-12-07 Impact factor: 3.633
Authors: A Nordenström; S F Ahmed; E van den Akker; J Blair; M Bonomi; C Brachet; L H A Broersen; H L Claahsen-van der Grinten; A B Dessens; A Gawlik; C H Gravholt; A Juul; C Krausz; T Raivio; A Smyth; P Touraine; D Vitali; O M Dekkers Journal: Eur J Endocrinol Date: 2022-04-21 Impact factor: 6.558
Authors: M C Maggio; A De Pietro; P Porcelli; F Serraino; T Angileri; A Di Peri; G Corsello Journal: Ital J Pediatr Date: 2018-02-13 Impact factor: 2.638
Authors: Renata C Scalco; Ericka B Trarbach; Edoarda V A Albuquerque; Thais K Homma; Thais H Inoue-Lima; Mirian Y Nishi; Berenice B Mendonca; Alexander A L Jorge Journal: Endocr Connect Date: 2019-11 Impact factor: 3.335